New cancer drug AL58805 enters first human tests
NCT ID NCT07179081
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial is testing an oral drug called AL58805 in 40 people with advanced solid tumors who have run out of standard treatment options. The main goals are to find a safe dose, identify side effects, and understand how the drug moves through the body. Researchers will start with low doses and gradually increase them in different groups of patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AL58805 (oral drug)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 40 participants, focused on safety and dosing. It is not designed to prove effectiveness, and many early-stage cancer drugs do not advance to later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410013, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?